Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 17:12:2943-2959.
doi: 10.2147/IDR.S218638. eCollection 2019.

Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review

Affiliations

Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review

Taher Azimi et al. Infect Drug Resist. .

Abstract

Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant Mycobacterium infection following limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic has adversely affected control programs, thus necessitating the study of the role bacteriophages in the treatment of mycobacterial infection. Bacteriophages are viruses that are isolated from several ecological specimens and do not exert adverse effects on patients. Phage therapy can be considered as a significant alternative to antibiotics for treating MDR and XDR mycobacterial infections. The useful ability of bacteriophages to kill Mycobacterium spp has been explored by numerous research studies that have attempted to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial infections. However, there are restricted data about phage therapy for treating mycobacterial infections. This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease.

Keywords: mycobacteria infection; mycobacteriophage; phage therapy; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

All of the authors declare that there are no commercial, personal, political, and any other potential conflicting interests related to the published manuscript.

Figures

Figure 1
Figure 1
Steps involved in phage mediated Mycobacterium tuberculosis lysis using Mycobacterium smegmatis.
Figure 2
Figure 2
Steps involved in phage TM4 mediated Mycobacterium tuberculosis lysis using liposome.
Figure 3
Figure 3
Overview of phage D29 mediated Mycobacterium tuberculosis lysis.
Figure 4
Figure 4
Steps involved in phage T7 mediated Mycobacterium tuberculosis lysis.
Figure 5
Figure 5
Overview of phage P4 mediated Mycobacterium tuberculosis lysis.
Figure 6
Figure 6
Overview of phage BTCU-1 mediated Mycobacterium tuberculosis lysis.
Figure 7
Figure 7
Overview of phage SWU1 mediated Mycobacterium tuberculosis lysis.
Figure 8
Figure 8
Overview of phage MS6 mediated Mycobacterium tuberculosis lysis.

Similar articles

Cited by

References

    1. Gondil V, Chhibber S. Exploring potential of phage therapy for tuberculosis using model organism. Biomed Biotechnol Res J. 2018;2(1):9–15. doi:10.4103/bbrj.bbrj_93_17 - DOI
    1. Azimi T, Shariati A, Fallah F, et al. Mycobacterium tuberculosis genotyping using MIRU-VNTR typing. J Mazandaran Univ Med Sci. 2017;27(149):40–48.
    1. Azimi T, Nasiri MJ, Zamani S, et al. High genetic diversity among Mycobacterium tuberculosis strains in Tehran, Iran. J Clin Tuberc Other Mycobact Dis. 2018;11:1–6. doi:10.1016/j.jctube.2018.01.001 - DOI - PMC - PubMed
    1. Taghipour A, Azimi T, Javanmard E, et al. Immunocompromised patients with pulmonary tuberculosis; a susceptible group to intestinal parasites. Gastroenterol Hepatol Bed Bench. 2018;11(Suppl 1):S134–S139. - PMC - PubMed
    1. WHO. Global Tuberculosis Report 2018. World Health Organization; 2018.